Antisense oligonucleotides for the treatment of dyslipidaemia
- PMID: 22634577
- DOI: 10.1093/eurheartj/ehs084
Antisense oligonucleotides for the treatment of dyslipidaemia
Abstract
Antisense oligonucleotides (ASOs) are short synthetic analogues of natural nucleic acids designed to specifically bind to a target messenger RNA (mRNA) by Watson-Crick hybridization, inducing selective degradation of the mRNA or prohibiting translation of the selected mRNA into protein. Antisense technology has the ability to inhibit unique targets with high specificity and can be used to inhibit synthesis of a wide range of proteins that could influence lipoprotein levels and other targets. A number of different classes of antisense agents are under development. To date, mipomersen, a 2'-O-methoxyethyl phosphorothioate 20-mer ASO, is the most advanced ASO in clinical development. It is a second-generation ASO developed to inhibit the synthesis of apolipoprotein B (apoB)-100 in the liver. In Phase 3 clinical trials, mipomersen has been shown to significantly reduce plasma low-density lipoprotein cholesterol (LDL-c) as well as other atherogenic apoB containing lipoproteins such as lipoprotein (a) [Lp(a)] and small-dense LDL particles. Although concerns have been raised because of an increase in intrahepatic triglyceride content, preliminary data from long-term studies suggest that with continued treatment, liver fat levels tend to stabilize or decline. Further studies are needed to evaluate potential clinical relevance of these changes. Proprotein convertase subtilisin/kexin-9 (PCSK9) is another promising novel target for lowering LDL-c by ASOs. Both second-generation ASOs and ASOs using locked nucleic acid technology have been developed to inhibit PCSK9 and are under clinical development. Other targets currently being addressed include apoC-III and apo(a) or Lp(a). By directly inhibiting the synthesis of specific proteins, ASO technology offers a promising new approach to influence the metabolism of lipids and to control lipoprotein levels. Its application to a wide variety of potential targets can be expected if these agents prove to be clinically safe and effective.
Similar articles
-
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.
-
Mipomersen, an antisense apolipoprotein B synthesis inhibitor.Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. doi: 10.1517/13543784.2011.547471. Epub 2011 Jan 6. Expert Opin Investig Drugs. 2011. PMID: 21210756 Review.
-
Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.Drugs Today (Barc). 2011 Dec;47(12):891-901. doi: 10.1358/dot.2011.47.12.1722069. Drugs Today (Barc). 2011. PMID: 22348914 Review.
-
New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?Cardiovasc Drugs Ther. 2013 Dec;27(6):559-67. doi: 10.1007/s10557-013-6479-4. Cardiovasc Drugs Ther. 2013. PMID: 23913122 Review.
-
Antisense oligonucleotides for the treatment of dyslipidemia.Curr Pharm Des. 2011;17(9):950-60. doi: 10.2174/138161211795428830. Curr Pharm Des. 2011. PMID: 21418033 Review.
Cited by
-
Regulation of Antisense Transcription by NuA4 Histone Acetyltransferase and Other Chromatin Regulatory Factors.Mol Cell Biol. 2016 Jan 11;36(6):992-1006. doi: 10.1128/MCB.00808-15. Mol Cell Biol. 2016. PMID: 26755557 Free PMC article.
-
Acute targeting of general transcription factor IIB restricts cardiac hypertrophy via selective inhibition of gene transcription.Circ Heart Fail. 2015 Jan;8(1):138-48. doi: 10.1161/CIRCHEARTFAILURE.114.001660. Epub 2014 Nov 14. Circ Heart Fail. 2015. PMID: 25398966 Free PMC article.
-
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.J Cardiovasc Dev Dis. 2024 Apr 21;11(4):126. doi: 10.3390/jcdd11040126. J Cardiovasc Dev Dis. 2024. PMID: 38667744 Free PMC article. Review.
-
Lipoprotein (a): Underrecognized Risk with a Promising Future.Rev Cardiovasc Med. 2024 Nov 6;25(11):393. doi: 10.31083/j.rcm2511393. eCollection 2024 Nov. Rev Cardiovasc Med. 2024. PMID: 39618878 Free PMC article. Review.
-
From methylene bridged diindole to carbonyl linked benzimidazoleindole: Development of potent and metabolically stable PCSK9 modulators.Eur J Med Chem. 2020 Nov 15;206:112678. doi: 10.1016/j.ejmech.2020.112678. Epub 2020 Aug 4. Eur J Med Chem. 2020. PMID: 32823006 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous